NCT03108131 2025-05-28Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsM.D. Anderson Cancer CenterPhase 2 Completed49 enrolled 10 charts
NCT02091141 2024-07-23My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsGenentech, Inc.Phase 2 Completed673 enrolled 22 charts
NCT04177108 2024-03-27A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast CancerHoffmann-La RochePhase 3 Completed242 enrolled 12 charts
NCT03637764 2023-07-10Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced MalignanciesSanofiPhase 1/2 Terminated107 enrolled 30 charts
NCT02458638 2021-06-04A Study of Atezolizumab in Advanced Solid TumorsHoffmann-La RochePhase 2 Completed474 enrolled 14 charts